CRISPR Therapeutics CRSP Deferred Tax Assets and Other Non-Current Assets
Deferred Tax Assets and Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's deferred tax assets and other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's deferred tax assets and other non-current assets?
- CRISPR Therapeutics (CRSP) reported deferred tax assets and other non-current assets of $28.98M in Q1 2026.
- How has CRISPR Therapeutics's deferred tax assets and other non-current assets changed year-over-year?
- CRISPR Therapeutics's deferred tax assets and other non-current assets increased by 39.5% year-over-year, from $20.78M to $28.98M.
- What is the long-term trend for CRISPR Therapeutics's deferred tax assets and other non-current assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's deferred tax assets and other non-current assets has grown at a 79.9% compound annual growth rate (CAGR), from $1.29M to $24.37M.